Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. Show more
Location: 628 Middlefield Road, Palo Alto, CA, 94301, United States | Website: https://kalaristx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
84.72M
52 Wk Range
$2.14 - $24.15
Previous Close
$4.53
Open
$4.53
Volume
80,754
Day Range
$4.41 - $4.81
Enterprise Value
92.06M
Cash
88.43M
Avg Qtr Burn
-8.04M
Insider Ownership
16.18%
Institutional Own.
69.90%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TH103 Details Neovascular Age-Related Macular Degeneration | Phase 1/2 Data readout |